Erasca, Inc.
ERAS
Positions held
Your positionsERAS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Erasca, Inc. operates in the biotechnology sector, focusing on innovative cancer therapies, which positions it well in a growing industry with increasing demand for targeted treatments.
- Erasca has a market cap of approximately $5 billion, indicating significant investor interest and potential for growth.
- The company's target mean price is $24.11, suggesting a potential upside from its current trading levels.
- Erasca has reported no revenue for multiple quarters, indicating challenges in commercializing its products.
- In the most recent quarter (2026-Q1), the company reported a net income loss of $183.44 million, reflecting ongoing financial struggles.
- The company's score indicates a 'Sell' signal with a score of -5.00, highlighting negative market sentiment and performance trends.
Fundamentals
| Market cap | $5.41B | Enterprise value | $5.18B | Trailing P/E | — | Forward P/E | -24.81 |
| PEG | — | Price / book | 13.35 | Beta | 0.62 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -78.2% | ROA | -21.4% | Debt / equity | 0.12 |
| Current ratio | 8.29 | Free cash flow | -$210.46M | Analyst recommendation | none | Mean target | $24.11 |
| 52w high | $24.28 | 52w low | $2.11 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$44.1M | -$183M | -$29.1M | -$30.6M | -$33.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$47.6M | -$37.9M | -$32.6M | -$32.5M | -$30.6M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$125M | -$162M | -$125M | -$243M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$131M | -$157M | -$142M | -$145M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-22 · Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
2026-09-10 · Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
2026-09-08 · Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-04 · FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
2026-08-24 · Erasca's ERAS-0015 Gets FDA Fast Track Designation for Metastatic Pancreatic Cancer
2026-08-14 · BofA Adjusts Price Target on Erasca to $20 From $18
2026-08-11 · Erasca Reports Second Quarter 2026 Business Updates and Financial Results
2026-08-10 · Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-16 · Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
2026-07-15 · Erasca Closes $632.5 Million Upsized Common Stock Offering
Price (daily)
Full chart · RSI · MACD · patterns